Cornell tests weekly obesity therapy to help overweight cats live longer
A new clinical study has begun at Cornell University to test a once-weekly weight-management therapy for cats. The treatment, developed by Akston Biosciences, targets feline obesity—a growing issue affecting over 60% of U.S. cats. Early lab tests showed no harmful effects in the animals involved.
The therapy uses a GLP-1 protein to help cats control their appetite. Built on Akston’s Fc-fusion platform, it is designed for simple, weekly dosing. Preclinical trials at Cornell found no unexpected affects in laboratory cats.
The study will now evaluate the treatment in client-owned cats over roughly three months. Researchers aim to enrol 70 overweight felines, with the option to expand to 140. Screening for the first participants has already started.
Akston is also working on a similar GLP-1 programme for dogs, though it remains about six months behind the feline version. Todd Zion, the company’s CEO, stated the goal is to improve cats’ longevity and health. Patrick Carney, a Cornell veterinary professor, called the research a potential breakthrough in managing feline obesity.
The trial marks a step toward addressing obesity in cats, a condition affecting millions in the U.S. alone. If successful, the therapy could offer a practical, long-term solution for pet owners. Results from the three-month study will determine next steps for the treatment.
